Rescheduling is here, in part. On April 22, 2026, a final order signed by Acting Attorney General Todd Blanche moved a defined set of marijuana products from Schedule I to Schedule III of the Controlled Substances Act.
FDA-approved products that contain marijuana and marijuana tied to qualifying state-issued medical licenses are now federally rescheduled. Everything else, including unlicensed bulk marijuana, adult-use marijuana and synthetically derived THC, remains in Schedule I. Hemp is unaffected. Operators who fit the rescheduled scope have an immediate opportunity; operators outside it have a new federal line to manage.
So, how can operators navigate this new federal landscape and prepare for the regulatory changes that lie ahead?
In this month’s special report, the experts at Green Check – the trusted infrastructure powering compliant, scalable commerce in the cannabis industry – break down highlights, takeaways and key dates from the final order.
This report provides operators with:
- 6 things to take away from rescheduling
- The practical effects of what moved, what stayed and why
- A worked example of the 280E tax relief picture
- Checklists you can use this quarter that cover:
1.) Licensing and Supply Chain
2.) Finance and Accounting - The hemp inflection point and its competitive dimension
- 4 questions you can put to your bankers now
- 3 disciplines to build durable business operations moving forward
The final order is narrow, but real, and additional refinements are to come. Don’t miss these insights to prepare for what’s ahead.
This report is available through May 2026 only – Get it while it’s here!